Renal Toxicity
5
0
0
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
8 treatments under study, led by Liver Biopsy
Research Leaders
7 sponsors active, led by Wyeth is now a wholly owned subsidiary of Pfizer
Related Conditions
Often studied with 8 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 5 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (5)
Study of Adverse Renal Effects of Immune Checkpoints Inhibitors
Kidney Dysfunction in Children and Young Adults Who Have Received Methotrexate for Acute Lymphoblastic Leukemia
Switching From One Type of Anti-rejection Drug (Tacrolimus or Cyclosporine) to Another (Sirolimus) Approximately 90-180 Days After Liver Transplantation
Frequency and Clinical Significance of Renal and Bone Toxicity in HIV-infected Patients
Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors
Research Network
Common Treatments
- Liver Biopsy1
- Medical Chart Review1
- Cisplatin1
- Assessment Of Therapy Complications1
- Renal Tolerance To Immunotherapy1
Active Sponsors
- Wyeth is now a wholly owned subsidiary of Pfizer1
- National Cancer Institute (NCI)1
- Vanderbilt University Medical Center1
- Asociacion para el Estudio de las Enfermedades Infecciosas1
- Hospices Civils de Lyon1
Top Investigators
Ramon y Cajal Hospital
Vanderbilt-Ingram Cancer Center
Institut Claudius Regaud
Thomas Jefferson University and Hospital
Related Conditions
- Neurotoxicity1
- Side Effects Of Calcineurin Inhibitors1
- Adverse Effect1
- Unspecified Adult Solid Tumor Protocol Specific1
- Leukemia1